Fat­taey out, Dentzer up at Curis; Bel­gian in­vestors back Span­ish or­phan drug biotech; Ve­rastem scores Chi­na deal

→ Spain’s Mi­no­ryx Ther­a­peu­tics has raised €21.3 mil­lion ($24.9 mil­lion) to ex­plore new us­es of its lead drug, thanks to strong back­ing from a group of Bel­gian play­ers that led the round, name­ly Fund+, SF­PI, S.R.I.W. and Sam­brin­vest. The biotech be­lieves that MIN-102 — cur­rent­ly in Phase II/III for adreno­myeloneu­ropa­thy — may al­so work in oth­er neu­rode­gen­er­a­tive dis­eases as well as neu­roin­flam­ma­to­ry con­di­tions like cere­bral ALD. Dur­ing its Se­ries A, the com­pa­ny at­tract­ed a long list of in­vestors, in­clud­ing Roche’s ven­ture fund, which all par­tic­i­pat­ed in the cur­rent Se­ries B.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER